Akebia Therapeutics, Inc. (AKBA)

Several events have impacted AKBA's stock price over the past six months. Akebia announced corporate updates regarding its Vafseo commercial business and pipeline outlook, including an increase in Vafseo prescribers and anticipated revenue growth, but the stock decreased. The company dosed the first patient in a Phase 2 clinical trial for praliciguat. Akebia's Q3 2025 earnings call highlighted a revenue surge. Akebia's stock slumped after the company announced it would not pursue a broad label expansion for Vafseo. The stock had experienced a negative return over the preceding six months. Analyst ratings suggested a potential upside for the stock.

Specific seasonal patterns for Akebia Therapeutics' product demand are not explicitly detailed, but the nature of its products suggests a more consistent demand. The company anticipates revenue growth for Vafseo to resume due to increased patient access and expected improvements in adherence and compliance.

Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for kidney diseases. Its major commercial products include Auryxia, used to control serum phosphorus levels and treat iron deficiency anemia in chronic kidney disease patients, and Vafseo, an oral HIF-PH inhibitor approved for anemia treatment in dialysis patients. Akebia also has product candidates in its pipeline, including AKB-9090 for acute kidney injury, AKB-10108 for retinopathy of prematurity, and AKB-097 for rare kidney diseases.

Akebia Therapeutics is headquartered in Cambridge, Massachusetts, United States. Auryxia's commercial operations are focused on the United States. Vafseo is commercialized in the U.S., Japan, and other Asian countries.

Akebia Therapeutics' brand reputation has been influenced by both positive developments and challenges. The FDA approval of Vafseo was a transformational milestone. The company disclosed a material weakness in its financial reporting controls. The announcement that the company would not pursue a broad label expansion for Vafseo led to a stock drop. Positive corporate updates regarding Vafseo's commercial performance and pipeline progress could contribute positively to its reputation.

Akebia Therapeutics has a mixed ownership structure. Institutional ownership includes major shareholders such as BlackRock, Inc. and Vanguard Group Inc. Approximately 2.26% of the company's stock is owned by insiders, including CEO John P. Butler. Retail investors hold approximately 69.10% of Akebia Therapeutics' stock.